echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Brain: These factors are associated with early-stage multiple sclerosis progression and relapse!

    Brain: These factors are associated with early-stage multiple sclerosis progression and relapse!

    • Last Update: 2022-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Demyelinating diseases are a class of acquired diseases with different etiologies and different clinical manifestations, but with similar characteristics.
    The characteristic pathological changes are the demyelination of nerve fibers and the relatively intact nerve cells
    .


    The function of myelin sheath is to protect neurons and make nerve impulses transmit quickly on neurons, so the loss of myelin sheath will affect the transmission of nerve impulses


    Demyelinating diseases are a class of acquired diseases with different etiologies and different clinical manifestations, but with similar characteristics.


    Among them, multiple sclerosis (MS) is the most common demyelinating disease


    Disability accumulation in multiple sclerosis may occur with relapse-related exacerbation or progression independent of relapse activity


    The aim of this study was to investigate the contribution of relapse-related worsening and progression independent of relapsing activity to the accumulation of confirmed disability in patients with clinically isolated syndrome and early-stage relapsing-remitting MS, assessed within one year of onset, with follow-up >/=5 Years (n = 5169)
    .


    Disability accumulation was defined as an increase in the Expanded Disability Status Scale score demonstrated over a 6-month period, categorized by temporal relationship to relapse


    The aim of this study was to investigate the contribution of relapse-related worsening and progression independent of relapsing activity to the accumulation of confirmed disability in patients with clinically isolated syndrome and early-stage relapsing-remitting MS, assessed within one year of onset, with follow-up >/=5 Years (n = 5169)


    During 11.


    Imaging differences in patients with different types of MS

    Imaging differences in patients with different types of MS

    Relapse-related worsening was associated with younger age at baseline (HR = 0.
    87; 95CI 0.
    81-0.
    93), a relapse-remitting course at baseline (HR = 1.
    55; 95CI 1.
    35-1.
    79), and lower Extended Disability Status Scale at baseline (HR=0.
    94; 95CI 0.
    89-0.
    99,), and more pre-event recurrences (HR=1.
    04; 95CI 1.
    01-1.
    07)
    .


    At the same time, longer exposure to disease-modifying drugs was associated with lower risk of both progression independent of relapse activity and relapse-related exacerbation (p < 0.


    Relapse-related worsening was associated with younger age at baseline (HR = 0.


    Taken together, progression independent of relapsing activity is an important factor in confirming disability accumulation in the early relapsing MS cohort


    references:

    references:

    Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study , Brain, 2022;, awac111, https://doi.


    Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study , Brain, 2022;, awac111, https://doi.
    org/10.
    1093/brain/awac111 Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.